Apimeds Pharmaceuticals US, Inc. (APUS) — Financial Flexibility Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Financial Flexibility Index of -1.56x as of September 2025. Free cash flow of $-1.70 Million (operating CF $-1.73 Million minus capex $22.54K) represents -2% of total liabilities ($1.09 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Apimeds Pharmaceuticals US, Inc. Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for Apimeds Pharmaceuticals US, Inc. across 4 annual periods. See working capital to net assets of Apimeds Pharmaceuticals US, Inc. to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Apimeds Pharmaceuticals US, Inc. (2021–2024)
Year-by-year free cash flow to debt coverage for Apimeds Pharmaceuticals US, Inc.. For the full company profile including market capitalisation, see Apimeds Pharmaceuticals US, Inc. stock valuation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | $-733.53K | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $-823.11K | $410.65K | — |